Brought to you by 
Horizon Pharma acquires worldwide rights to BI's interferon gamma-1b
15 Nov 2021
Executive Summary
Horizon Pharma PLC received worldwide rights to Boehringer Ingelheim GmbH's interferon gamma-1b product (trade names Imuki, Imukine, Immukin, Immukine and Actimmune; Horizon already owns rights to the product as Actimmune in US, Canada and Japan). Under the agreement the two parties will also enter into a global supply agreement.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Horizon Pharma acquires worldwide rights to BI's interferon gamma-1b
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice